438 related articles for article (PubMed ID: 17108119)
1. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
Nystrom ML; McCulloch D; Weinreb PH; Violette SM; Speight PM; Marshall JF; Hart IR; Thomas GJ
Cancer Res; 2006 Nov; 66(22):10833-42. PubMed ID: 17108119
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation.
Yap LF; Jenei V; Robinson CM; Moutasim K; Benn TM; Threadgold SP; Lopes V; Wei W; Thomas GJ; Paterson IC
Oncogene; 2009 Jul; 28(27):2524-34. PubMed ID: 19448673
[TBL] [Abstract][Full Text] [Related]
3. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A
Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747
[TBL] [Abstract][Full Text] [Related]
4. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Dormond O; Foletti A; Paroz C; Rüegg C
Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
[TBL] [Abstract][Full Text] [Related]
5. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
Kwak YE; Jeon NK; Kim J; Lee EJ
Ann N Y Acad Sci; 2007 Jan; 1095():99-112. PubMed ID: 17404023
[TBL] [Abstract][Full Text] [Related]
6. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
7. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
Du Y; Zhang S; Wang Z; Zhou W; Luan M; Yang X; Chen N
Oncol Rep; 2008 Sep; 20(3):605-11. PubMed ID: 18695912
[TBL] [Abstract][Full Text] [Related]
9. Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells.
Ylipalosaari M; Thomas GJ; Nystrom M; Salhimi S; Marshall JF; Huotari V; Tervahartiala T; Sorsa T; Salo T
Exp Cell Res; 2005 Oct; 309(2):273-83. PubMed ID: 16024014
[TBL] [Abstract][Full Text] [Related]
10. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6.
Ramsay AG; Keppler MD; Jazayeri M; Thomas GJ; Parsons M; Violette S; Weinreb P; Hart IR; Marshall JF
Cancer Res; 2007 Jun; 67(11):5275-84. PubMed ID: 17545607
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.
Morita Y; Hata K; Nakanishi M; Nishisho T; Yura Y; Yoneda T
Int J Oncol; 2012 Sep; 41(3):885-92. PubMed ID: 22735610
[TBL] [Abstract][Full Text] [Related]
12. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
DiBernardi L; Doré M; Davis JA; Owens JG; Mohammed SI; Guptill CF; Knapp DW
Prostaglandins Leukot Essent Fatty Acids; 2007 Apr; 76(4):245-50. PubMed ID: 17383864
[TBL] [Abstract][Full Text] [Related]
13. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
Lee DW; Sung MW; Park SW; Seong WJ; Roh JL; Park B; Heo DS; Kim KH
Anticancer Res; 2002; 22(4):2089-96. PubMed ID: 12174888
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
[TBL] [Abstract][Full Text] [Related]
16. Role of the alpha(v)beta6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro.
Xue H; Atakilit A; Zhu W; Li X; Ramos DM; Pytela R
Biochem Biophys Res Commun; 2001 Nov; 288(3):610-8. PubMed ID: 11676487
[TBL] [Abstract][Full Text] [Related]
17. Activated Vav2 modulates cellular invasion through Rac1 and Cdc42 in oral squamous cell carcinoma.
Lai SY; Ziober AF; Lee MN; Cohen NA; Falls EM; Ziober BL
Oral Oncol; 2008 Jul; 44(7):683-8. PubMed ID: 17996485
[TBL] [Abstract][Full Text] [Related]
18. [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Réti A
Magy Onkol; 2010 Dec; 54(4):377-81. PubMed ID: 21163769
[TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Segawa E; Sakurai K; Kishimoto H; Takaoka K; Noguchi K; Hashitani S; Hirota S; Urade M
Oral Oncol; 2008 Jul; 44(7):664-71. PubMed ID: 17996482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
